Pablo Corral Shares New Insights: Genome Editing and Gene Therapy for Lipid Disorders
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A must read article
‘Gene therapy and genome editing for lipoprotein disorders‘ provides a comprehensive and timely overview of how advances in genetic medicine—including AAV gene addition, CRISPR editing, and RNA-based strategies—are reshaping the prevention and management of dyslipidaemias and ASCVD.
This open-access article highlights how innovative approaches may overcome limitations of lifelong lipid-lowering therapy, address unmet clinical needs in familial and polygenic disorders, and integrate polygenic risk scores and machine learning to personalize cardiovascular prevention.
An excellent resource for clinicians, researchers, and students interested in the rapidly evolving field of cardiovascular genetics.”
Title: Gene therapy and genome editing for lipoprotein disorders
Authors: Chen Gurevitz, Archna Bajaj, Amit V Khera, Ron Do, Heribert Schunkert, Kiran Musunuru, Robert S Rosenson
Read the full paper here.
Stay informed with Hemostasis Today.
-
Sep 18, 2025, 06:50Fetal Hereditary TTP Featured in NEJM – Senior Author Nishant Rajendra Tiwari
-
Sep 17, 2025, 10:54Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
-
Sep 17, 2025, 08:16Superficial Vein Thrombosis Management: John Fanikos Shares Latest Review
-
Sep 17, 2025, 07:00Maha Othman - ''BIC 2025 is Without a Doubt a Remarkable Scientific Event — and I’m Excited for What Lies Ahead!''
-
Sep 16, 2025, 11:17Glenn Pierce: WHO Issues a Biannual Essential Medicines List
-
Sep 18, 2025, 07:00Rishabh Singh on NEJM Letter: FVIII Aurora Mutation Shows Increased Activity and Reduced APC Response
-
Sep 18, 2025, 02:25Flora Peyvandi Highlights 'Inflammatory Memory of Stem Cells' – New Insights for Hematologic Diseases
-
Sep 17, 2025, 16:32Endovascular Today: Dr. Eric Secemsky Analyzes Impact of Paclitaxel Pause on Peripheral Artery Disease Care
-
Sep 17, 2025, 16:28Haemnet Showcases Research on Severe Haemophilia A Patients Adapting to Emicizumab Therapy
-
Sep 17, 2025, 16:19Todd Villines: Coronary Artery Disease - A BIG Movement to Change
-
Sep 16, 2025, 14:59A New Era in Antiplatelet Therapy for CABG?
-
Sep 16, 2025, 07:44Artificial Blood Breakthrough in Japan: Long Shelf Life, No Type Matching, and a Purple Future
-
Sep 16, 2025, 02:44Wolfgang Miesbach Highlights First Inhibitor Case After Hemophilia A Gene Therapy (Giroctocogene Fitelparvovec)
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 18, 2025, 06:34'A New Era in Mechanical Thrombectomy?' – Sripal Bangalore Highlights SYMPHONY-PE IDE Study
-
Sep 17, 2025, 10:49Living with Glanzmann Thrombasthenia․ Eliza VanZweden’s Story of Resilience and Advocacy
-
Sep 17, 2025, 10:22Abdul Mannan: Turning Medical Podcasts into Active Learning with Structured Tools
-
Sep 17, 2025, 09:43Global Blood Supply Under Threat: David McIntosh Calls for Action to Support Transfusion Services
-
Sep 17, 2025, 09:08Coronary Arteries, Pericardial Cavity, and the Hidden Danger of Cardiac Tamponade During PCI-By Ahmed Ata